Researchers from Delix Therapeutics Inc. recently presented preclinical pharmacology data for DLX-001, a novel orally bioavailable, nonhallucinogenic neuroplastogen being developed for the treatment of neuropsychiatric diseases.
Axonal degeneration is a key early pathogenic driver of amyotrophic lateral sclerosis and other neurodegenerative diseases. Activation of calpain-2 (CAPN2) is thought to be the critical effector behind axonal degeneration. Amylyx Pharmaceuticals Inc. has presented data on their CAPN2 inhibitor antisense oligonucleotide (ASO) AMX-0114 as a potential therapeutic for axonal degeneration.
Abbvie Inc.’s encore to its $10.1 billion buyout of antibody-drug conjugate specialist Immunogen Inc. took the form of another takeover – this time of Cerevel Therapeutics Inc. for $45 per share in cash, which puts the total equity value at about $8.7 billion and provides Abbvie with “one of the most attractive growth portfolios in the industry,” CEO Richard Gonzalez said.
Sosei Group Corp. has reported clinical development plans by its partner Neurocrine Biosciences Inc. for two new oral muscarinic receptor agonist candidates, NBI-1117569 and NBI-1117567.
Enveric Biosciences Inc. has identified three novel compounds from its EVM301 series with the potential to offer a first-in-class approach to address difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations.
Researchers have defined an amyotrophic lateral sclerosis (ALS) reversal phenotype as having an initial diagnosis of ALS but subsequently showing a progressive and sustained clinical improvement, based on an unusual case they found.
Voyager Therapeutics Inc. has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program. The company anticipates filing an IND application for the candidate with the FDA in mid-2025.
Bsense Bio Therapeutics Ltd. has nominated BSEN-760, a dual Kv7.2/3 and TRPV1 ion channel modulator, as a clinical candidate for the treatment of chronic pain.
At the recent American College of Neuropsychopharmacology meeting, Trevena Inc. presented preclinical data for the novel selective sphingosine 1-phosphate S1P1 receptor modulator TRV-045, being developed for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
China’s National Medical Products Administration (NMPA) approved Zhejiang Jingxin Pharmaceutical Co. Ltd.’s dimdazenil (EVT-201) for short-term treatment of insomnia. Jingxin filed the NDA in China in April 2022.
RSS
